Specialty Pharma Journal

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX:…
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq: INCY) today announced that data from th…
Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded

SAN CARLOS, Calif., Sept. 2, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and le…
Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion

BRISBANE, Calif.–(BUSINESS WIRE)–Aug. 31, 2020– Aimmune Therapeutics Inc. (Nasdaq:…
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (Nasdaq: TWST) …

The 2017 Hepatitis C Treatment Landscape

February 22, 2017 Blog

Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, …
Read More »
Understanding the Hepatitis C Testing Process

February 15, 2017 Blog
Potential New Medication for Lymphoma

February 8, 2017 Blog

FDA Approves Stelara for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

July 31, 2020 FDA News, Psoriasis

HORSHAM, Pa., July 30, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the …

Guardant Health and Radius Health Partner to Develop Liquid Biopsy Companion Diagnostic for Elacestrant

July 31, 2020 Business News, Oncology, Technology & Devices

REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) — Guardant Health, Inc. (Nasdaq: GH) today announced …

AstraZeneca’s Tagrisso Granted Breakthrough Therapy Designation by the FDA for Treatment of Patients with Stage IB-IIIA EGFR-Mutated Lung Cancer

July 30, 2020 FDA News, Oncology

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s TAGRISSO® (osimertinib) has been granted Breakthrough Therapy Designation (BTD) in the US for the …

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

July 30, 2020 Business News

BRISBANE, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it …

FDA Grants Breakthrough Therapy Designation to Takeda’s Pevonedistat for Treatment of Higher-Risk Myelodysplastic Syndromes

July 30, 2020 FDA News, Oncology

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. …

Merck Announces Two FDA Regulatory Milestones for Keytruda in Triple-Negative Breast Cancer

July 30, 2020 FDA News, Oncology

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today …

Imara’s IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia

July 30, 2020 FDA News, Rare Diseases

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) — IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company …

Nirsevimab Reduced Respiratory Syncytial Virus Infections Requiring Medical Care in Healthy Premature Infants in Phase 2b Trial

July 30, 2020 Respiratory Syncytial

READING, England–(BUSINESS WIRE)– Detailed results from the positive Phase 2b trial for nirsevimab showed a …

Bristol Myers and bluebird bio Announce Submission of BLA to the FDA for Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma

July 30, 2020 FDA News, Oncology

PRINCETON, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today …

FDA Approves Roche’s Ventana HER2 Dual ISH Test as a Companion Diagnostic to Identify Breast Cancer Patients Eligible for Targeted Therapy

July 30, 2020 FDA News, Oncology, Technology & Devices

Basel, 29 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food …

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

July 30, 2020 Specialty Pharmacy

NORTH CHICAGO, Ill., July 29, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the Phase 3 …

UCB and Roche Collaborate to Develop Antibody Treatment for People Living with Alzheimer’s Disease

July 30, 2020 Business News

BRUSSELS, July 29, 2020 /PRNewswire/ — UCB today announced an agreement to enter into a …

FDA Grants Breakthrough Therapy Designation to Merck’s MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma

July 30, 2020 FDA News, Oncology

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced …

Genentech’s Phase 3 Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia Fails to Meet its Primary Endpoint

July 30, 2020 Infectious Diseases

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …

Farxiga Met All Primary and Secondary Endpoints in Groundbreaking Phase 3 Trial for the Treatment of Patients with CKD

July 30, 2020 Renal Diseases

WILMINGTON, Del.–(BUSINESS WIRE)–High-level results from FARXIGA®’s (dapagliflozin) Phase III DAPA-CKD trial showed a statistically significant …

Page 10 of 325« First...8 91011 12 »20 30 40...Last »

Recent Posts